Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved docetaxel in combination with carboplatin, trastuzumab (s/c), and pertuzumab (tch(s/c)p) therapy for reimbursement as a treatment option for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early breast cancer at high risk of recurrence in adult patients.
This is written in the approval document as:
Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | HER2-positive | Invasive Breast Carcinoma | Carboplatin, Docetaxel, Pertuzumab, Trastuzumab |